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Summary Aberrant Wnt gene expression is involved in the development of breast cancer, but its role in other tumours is unknown. Wnts
regulate cadherin function, previously shown to be more commonly deregulated in invasive bladder cancer. This study investigated whether
factors upstream of cadherins were aberrantly expressed in superficial bladder cancer. The expression of one transforming (Wnt7b) and one
non-transforming (Wnt5a) Wnt gene in four human bladder carcinoma cell lines, and in normal human bladder tissues (n = 8) and bladder
cancers (n = 48) were analysed by ribonuclease protection analysis. All cell lines expressed an approximately equal level of Wnt7b mRNA.
Wnt5a and Wnt7b mRNAs were both expressed in normal bladder tissues and bladder tumours. The median expression of Wnt7b was
fourfold higher in superficial tumours (n = 29) than in normal tissues (n = 8, P = 0.002) and five fold higher than in invasive tumours (n = 17,
P= 0.003). There was no significant difference between normal tissues and invasive tumours (P= 0.3). The expression of Wnt5a did not vary
significantly between normal tissues and superficial tumours (P = 0.4), normal tissues and invasive tumours (P = 0.3) or superficial tumours
and invasive tumours (P = 0.2). The differential expression of Wnt7b suggests a role in the early events of superficial bladder tumorigenesis
involving cell adhesion and provides further evidence of different pathways of evolution of superficial and invasive cancer.
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Superficial bladder cancers have a highly variable behaviour, with
30% showing multifocality and 60-70% recurring, but others may
never recur. Recurrences may be clonal in some cases, with lateral
epithelial spread or intravesical 'seeding' as potential mechanisms.
Thus mechanisms regulating cell adhesion are highly relevant to
the biology of superficial bladder cancer. Several studies have
recently examined the expression ofE-cadherin, ahomotypic inter-
cellular adhesion molecule in superficial and invasive bladder
cancer. In five studies, down-regulation or aberrant localization of
E-cadherin was found in the majority of invasive cancers and was
associated with a poor prognosis (Bringuier et al, 1993; Syrigos et
al, 1995; Witjes et al, 1995; Griffiths et al, 1996; Shimazui et al,
1996; Wakatsuki et al, 1996). In the superficial tumours, only the
minority (3 of20, Shimazui et al, 1996; 3 of 15, Syrigos etal, 1995;
7 of 22, Griffiths et al, 1996; and 11 of 34, Wakatsuki et al, 1996)
showed changes in E-cadherin. Nevertheless, recurrence is more
common than this abnormal frequency ofE-cadherin expression.
Recently, another gene family has been shown to interact with
the E-cadherin/4-catenin system and to affect tumour growth;
these are the Wnt genes, which regulate turnover of P-catenin, a
cytoplasmic binding protein that interacts with E-cadherin and is
essential for E-cadherin function (Bradley et al, 1993; Hinck et al,
1994). The functional up-regulation of ,B-catenin by Wnt expres-
sion is similar in function to mutations in the oncogene APC
(adenomatous polyposis-coli gene) which also upregulate P-
catenin. A point mutantP-catenin with increased intracellular half-
life has been shown to be transforming (Whithead et al, 1995). The
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change in P-catenin half-life results in a free pool of 3-catenin that
can translocate transcription factors to the nucleus (Kuhl and
Wedlich, 1997). It may also interact with the epidermal growth
factor (EGF) receptor, which has been found to have an affect on
tumour prognosis in bladder cancer (Neal et al, 1990). It has been
suggested that one mechanism by which E-cadherin functions as a
tumour suppressor is sequestration of 1-catenin and the inhibition
of 3-catenin signalling activity (reviewed in Fagotto and
Gumbiner, 1996)
We therefore investigated whether this other pathway involving
cell adhesion and 3-catenin was up-regulated in superficial bladder
cancer, in contrast to the changes in E-cadherin in invasive bladder
cancer. This pathway, the Wnt gene family, was assessed by
nuclease protection assay in RNA samples from superficial and
invasive tumours.
The Wnt genes are a large family of developmental genes in
which the first member (int-i also known as Wntl) was discovered
from its role in mouse mammary tumorigenesis (Nusse and Varmus,
1992). Subsequently, numerous new Wnt genes have been isolated
from a variety of invertebrate and vertebrate species in which the
genes are highly conserved. Classically, Wnt genes encode a
cysteine-rich glycoprotein of -45 kDa and contain 22 conserved
cysteine residues that are important in their structure and/orfunction
(Mason et al, 1992). Wnt proteins are glycosylated and transported
to the cell surface by as yet unknown mechanisms (Brown et al,
1987; Papkoff et al, 1987; Kitajewski et al, 1992; Bradley and
Brown, 1995; Burrus and McMahon, 1995), where they are tightly
bound to the extracellular matrix via heparin-like binding sites
(Papkoff, 1989; Bradley and Brown, 1990; Papkoff and Schryver,
1990). Wnt-mediatedbiological responses includepattern formation
during embryogenesis and development (Nusse and Varmus, 1992;
Parr and McMahon, 1995), differentiation during kidney develop-
ment (Stark et al, 1994) and genesis of mouse mammary cancer
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Figure 1 Gene expression of Wnt5a (A) and Wnt7b (B) in human bladder
carcinoma cell lines using RNAase protection analysis. The upper panel
shows the Wnt protected fragment signal and the lower panel shows the
GAPDH protected fragment signal obtained from the same sample
TNM stage (UICC, 1992), pTarepresenting tumour notpenetrating
the laminapropria andpTl tumours penetrating the laminapropria.
To assess Wnt expression in epithelial cells representing a pure
population, human bladder carcinoma cell lines (T24, RT4, RTl 12
and 253J) were obtained from Dr MA Knowles, Marie Curie
Research Institute, Oxsted, Surrey, UK. RT4 cell line is aparadigm
for well-differentiated bladder carcinoma, RI 12 moderately differ-
entiated bladdercarcinoma, andT24 and 253J poorly differentiated
bladder carcinomas. All the cells were cultured in Dulbecco's
modified Eagle medium (DMEM) (Imperial Cancer Research
Fund, Clare Hall Laboratories) and 10% fetal calf serum (FCS)
(Globepharm). The cells were allowed to reach confluence before
harvest. Total RNA was prepared from tissues and cells using the
acid guanidium thiocyanate-phenol-chloroform extraction method
(Chomczynski and Sacchi, 1987), followed by a 5.7 M caesium
chloride separation at 50000 r.p.m. for 3 h using a SW50 or SW55
swing rotor (Beckman). The RNA pellet was resuspended in
200ml of sterile water, treated with RNAase-free DNAase for
15 min at 37°C, extracted with an equal volume ofphenol, ethanol
precipitated with 0.1 x volume of sodium acetate, pH 5.2, and
resuspended in water to the final concentration of 1 mg ml'.
Riboprobe constructs and RNAase protection analysis
The human Wnt5a (Lejeune et al, 1995), Wnt7b (Huguet et al,
1994) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(McCarthy and Bicknell, 1992) riboprobe constructs have been
described. The linearized Wnt5a, Wnt7b and GAPDH plasmid
DNAs were labelled with [a-32P]CTP to generate antisense ribo-
probes, which were thenpurifiedusing the SpinColumn according
to the manufacturer's instructions (Boehringer Mannheim).
RNAase protection analysis was performed on 10gg of total
RNA at 450C using standard protocols (Ausubel et al, 1990).
Autoradiography was done at -70°C with intensifying screens.
Yeast total RNA (Boehringer Mannheim) was used as a negative
control. The protected fragment signals for Wnt5a, Wnt7b and
GAPDH were quantified by laser densitometry using a Biolmage
analyser (Millipore). The level of Wnt mRNA expression was
shown as a ratio ofWnt/GAPDH protected fragment signals.
(Nusse and Varmus, 1992). High expression is reported in human
breast and other cancers (Huguet et al, 1994; lozzo et al, 1995;
Lejeune et al, 1995; Vider et al, 1996). In humans, eight Wnt genes
have been identified [Wnt: 1 (van Ooyen et al, 1985); 2 (Wainright
et al, 1988); 3 (Roelinketal, 1993); Sa(Clark etal, 1993; Lejeune et
al, 1995); and 3a, 4, 7a and 7b (Huguet et al, 1994)]. Wnt7b and
Wnt5a are up-regulated in human breast cancers. Wnt5a is also up-
regulated in lung, colon and prostate carcinomas and melanomas
(lozzo etal, 1995). Wnt2 isup-regulated in colon tumours compared
with non-tumorous tissues (Vider et al, 1996). These studies have
provided evidence for the role ofWnt genes in the development of
other human tumours.
MATERIALS AND METHODS
Tissue selection, cell culture and RNA preparation
The collection of normal human (n = 8) and tumour (n = 48)
bladder tissues has been described previously (O'Brien et al, 1995).
Samples were taken frombiopsies shown to be histologically repre-
sentative ofthe tumour. Tumour was staged using UICC criteria for
Statistical analysis
The level of expression of Wnt5a and Wnt7b in normal human
bladder and tumour tissues were compared using the
Mann-Whitney U-test (two tailed) from the Minitab version
8.2 to produce P-values. Correlation coefficient Z test was
performed using Statsview version 4.
RESULTS
Wnt5a and Wnt7b mRNA expression in human bladder
carcinoma cell lines
The level ofWnt5a mRNA was very high in the RT4 cell line that
was obtained from a well-differentiated bladder carcinoma,
moderately high and low in the 253J and T24 cell lines, respec-
tively, which were obtained from poorly differentiated bladder
carcinomas. There was no detectable Wnt5a mRNA in the RI 12
cell line that was obtained from a moderately differentiated
bladder carcinoma (Figure IA). Wnt7b mRNA expressed approxi-
mately equally in all cell lines (Figure 1B).
British Journal ofCancer (1998) 77(2), 319-324 0 CancerResearch Campaign 1998Expression of Wnt7b andbladdercancer 321
Normal pTa pT1 Invasive
A 0 °a° 0 C 8c 0 XX zD c i3 A a ° N 0 X- w w E
V
,Wnt5a undigested
_7 probe
Wnt5aprotected
fragment
GAPDH protected
fragment
Normal pTa pT1 Invasive
0 0 °
co Do cq
0 D e
w X
r e
0 w
ItT-0 m CMqt 0 w
Wnt7b undigested z_i_~~~~~~~~~~~~~~~~~~~~~~~~probe
Wnt7b protected
~~~~~~~~~~~~~~~~~~~~~~fragment
GAPDH protected
fragment
Figure 2 Gene expression of Wnt5a (A) and Wnt7b (B) in some representative normal human bladdertissues, pTa and pTl stages of superficial tumours
and invasive tumours using RNAase protection analysis. The upper panel shows the Wnt protected fragment signal in the lower band and the lower panel shows
the GAPDH protected fragment signal from the same sample. The sample numbers indicate their ID in our bladder RNA bank. GAPDH exposure time was 12 h
(A) and 2 days (B) to improve presentation. However, quantification was all done on 12-h exposure. Wnt5a and Wnt7b exposure time was 2 days
Wnt5a and Wnt7b mRNA expression in normal human
bladder tissues and bladder cancers
Nine ofthe tumours were pTa lesions, 22 were pTl lesions and 17
were invasive (pT2, 3, 4). Two of the invasive tumours were
predominantly squamous cell tumours, with all other tumours
being transitional cell in origin. All the pTa tumours had a papil-
lary morphology. Seventeen of the pTl tumours were papillary,
two were solid and three were mixed. Three of the invasive
tumours had apapillary morphology and 14 were solid. Wnt5a and
Wnt7b mRNA expression were detected in normal bladdertissues,
pTa and pTl stages ofsuperficial tumours and in invasive tumours
(Figure 2). The median expression ofWnt7b was fourfold higher
in superficial tumours (n = 29) than in normal tissue (n = 8, P =
0.002) and fivefold higher than in invasive tumours (n = 17, P =
0.003). There was no significant difference between normal tissues
and invasive tumour (P = 0.3) (Figure 3B, Table 1). The levels of
Wnt5a tnRNA in different groups (Figure 3A) showed no signifi-
cant difference in expression (Table 1). However, there was a wide
range of expression and a subgroup of cancers showed a high
expression. Five of29 (17%) superficial tumours and 1 of 16 (6%)
invasive tumours expressed > fourfoldhigher than the highest level
of Wnt5a in normal tissues. There was no protected fragment for
Wnt5a, Wnt7b or GAPDH in tRNA-negative control in all assays
(data not shown).
Correlation between the levels of Wnt5a and Wnt7b
mRNA expression
There was no significant correlation between the levels of
Wnt5a and Wnt7b mRNA expression in normal tissues and super-
ficial or invasive tumours alone, or in combined tumours (data
not shown).
Correlation between Wnt mRNA expression and
recurrence of superficial tumours
Follow-up on the 29 superficial tumours (seven pTa and 22 pTI)
showed 17 patients developed recurrenttumourby 1 year(fourpTa
and 13 pTl). There was nocorrelationbetween the levels ofWnt5a
or Wnt7b mRNA expression in the primary superficial tumours
and recurrence by 1 year (data not shown).
Correlation between Wnt mRNA expression and 1-year
survival in invasive tumours
Six patients (6 of 17) with invasive tumours died of their disease
within 1 yearofthe primary tumourresection. There was no corre-
lation between Wnt5a or Wnt7b mRNA expression and 1-year
survival (data not shown).
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Figure 3 Comparison of expression of Wnt5a (A) and Wnt7b (B) mRNA
levels in normal human bladder tissues, pTa and pTl stages of superficial
tumours and invasive tumours. Median levels of Wnt5a are: normal, 69; pTa,
104; pTl, 233; pTa+pTl, 226; and invasive, 130. Median levels of Wnt7b are:
normal, 34.5; pTa, 256; pTl, 96; pTa+pTl, 145; and invasive, 50. Indicates
significant difference compared with normal or invasive (see Table 1)
DISCUSSION
One way of investigating the role of new genes in human cancer
is to examine its differential mRNA and/or protein expression
between normal tissues and at different stages of tumour progres-
sion. In the case of human bladder cancer, protein overexpression
ofp53, c-erbB2 and epidermal growth factorreceptor (EGFR), and
decreased protein expression of E-cadherin and RB in bladder
tumours compared with normal tissues and in tumour progression
have been documented and are useful in assessing prognosis (Vet
et al, 1994).
Four recent studies have used this approach to study a develop-
mental gene 'family, Wnt, and showed an up-regulation of Wnt5a
mRNA in human breast carcinomas (Lejeune et al, 1995), colon,
lung and prostate carcinomas and melanoma (Tozzo et al, 1995;
Vider et al, 1996). The data presented here showed that Wnt5a
and Wnt7b mRNAs are expressed in normal bladder tissues and
bladder tumours. This study shows for the first time the up-regula-
tion ofa memberofthe Wnt gene family in human bladder cancer.
The up-regulation of Wnt7b in human malignancy has only
been reported previously in breast cancer in which it was up-regu-
lated 30-fold in 10% oftumours compared with normal and benign
tissues (Huguet et al, 1994). This study similarly shows that
Wnt7b may also have a role in the development ofbladder cancer
and is preferentially associated with the superficial pathway, with
a sevenfold up-regulation in pTa lesions. In vitro, Wnt7b has been
shown to possess the highest transforming ability out ofall human
Wnt genes (Wong et al, 1994).
Althoughthere was no overallup-regulation ofWnt5a mRNA in
bladder cancer, there was a small proportion of tumours (6 of 46,
13%) that expressed fourfold higher Wnt5a mRNA level than
normal tissues. Abnormalities and loss ofheterozygozity on chro-
mosome 3p occurs in 7.8% of bladder cancers (Knowles et al,
1994), and Wnt5a is located on 3pl4-p21 (Clark et al, 1993).
Therefore, it is possible that Wnt5a might be important in a
subpopulation ofbladder cancer.
Because of tissue heterogeneity, it is possible that the differ-
ences between tumour and normal epithelium were only due to a
low proportion of epithelium in the normal biopsies compared
with the tumours. This is unlikely because the invasive tumours
showed similar levels of Wnt expression to normal tissue, and
there were major differences in Wnt expression between the
superficial and the invasive tumours. The RNA extraction was
controlled using a control endogenous gene, and there were super-
ficial tumours showing similar levels ofWnt to normal tissue.
All the bladder carcinoma cell lines expressed Wnt7b, and RT4
was by farthehighestexpressorofWnt5amRNA. Itwas established
Table 1 Statistical analysis of Wnt5a and Wnt7b mRNA levels in normal human bladdertissues, pTa and pTl superficial tumours and invasive tumours by
Mann-Whitney test
P-value
Normal Normal Normal Normal pTa pTa pT1 pTa+pTl
Vs Vs Vs Vs Vs Vs Vs Vs
pTa pTl pTa+pT1 invasive pTl invasive invasive invasive
Wnt5a 0.4 0.4 0.4 0.9 0.7 0.1 0.3 0.2
Wnt7b 0.008* 0.005* 0.002* 0.3 0.09 0.011* 0.009* 0.003*
*Significant difference.
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from a well-differentiated tumour, which is thephenotype ofmost of
the tumours expressing high Wnt5a. Morphologically, RT4 is also
known to grow in island form rather than in the flattened form seen
intheotherthreecell lines, suggesting thatWnt5amRNAexpression
might be related to cell shape. A similar observation has been
reported in human mammary epithelial cell lines HB2 (and
MDA468) in which Wnt5a mRNA level decreased by twofold as
cells changed from flattened shape to spherical form, and decreased
by tenfold as cells changed from spherical form to branching
(Huguet et al, 1995). Therefore, Wnt5a may act as a modulator of
cell migration (Moon et al, 1993).
Thepossible roleforWntup-regulation mayberelated tochanges
in ,-catenin signalling, previously shown for Wntl in other tumour
types (breast cancer and a colon cancer cell line). This result
suggests that both superficial and invasive tumours have defects or
abnormalities in the genes regulating the P-catenin/E-cadherin
pathway but proceed via different mechanisms, supporting the
different genetic backgrounds to superficial and invasive bladder
cancer (Presti et al, 1991; Knowles et al, 1994; Vet et al, 1994).
Wnt7b was up-regulated in superficial tumours compared with
normal tissues and invasive tumours, suggesting a role forWnt7b in
the tumorigenesis ofsuperficial cancer or papillary structure forma-
tion. The direct role ofWnt7b can only be assessed in experimental
models, and transfection of Wnt 7b into superficial bladder cancer
cell lines and orthotopic xenografts are planned.
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